A phase I randomized, double‐blinded, placebo‐controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects

• Hauptverfasser: Jason Lickliter (VerfasserIn), Shuang Wang (VerfasserIn), Wenxin Zhang (VerfasserIn), Huaqiang Zhu (VerfasserIn), Jing Wang (VerfasserIn), Congqiao Zhao (VerfasserIn), Haige Shen (VerfasserIn), Yu Wang (VerfasserIn)
• Format: Buch
• Veröffentlicht: Wiley, 2023-09-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Receptor‐interacting protein kinase 1 (RIPK1) mediates necroptosis and inflammation in various pathophysiologies, emerging as a pharmacological target for neurodegenerative and inflammatory indications. This phase I, first‐in‐human, placebo‐controlled study evaluated the safety, pharmacokin...